Clinical trials
Observational Basal Cell Carcinoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 4 |
| National Cancer Institute (NCI) | 3 |
| Massachusetts General Hospital | 2 |
| Northwestern University | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
| DermaSensor, Inc. | 1 |
| Genentech, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| Philip Schaner | 1 |
| ProgenaBiome | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Basal Cell Carcinoma | 26 |
| Carcinoma, Squamous Cell | 16 |
| Skin Neoplasms | 12 |
| Melanoma | 9 |
| Carcinoma, Merkel Cell | 2 |
| Cutaneous Squamous Cell Carcinoma | 2 |
| Neoplasms | 2 |
| Anthrax | 1 |
| Autoimmune Diseases | 1 |
| Basal Cell Nevus Syndrome | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.